Only China locations: HEC169096 in Participants With Advanced Solid Tumors

Inclusion criteria:
Phase 1: diagnosed non-resectable advanced solid tumor.
Phase 2: All participants must have an oncogenic RET-rearrangement/fusion or mutation solid tumor.

Sponsor/Collaborator: Sunshine Lake Pharma Co., Ltd.

Contact and Locations:
Study contact: GuangDong Province Peoples Hospital. Haiyan Tu.
Phone Number: 13798012949
Email: tuhaiyan@gdph.org.cn

Mechanism of action: Highly-selective RET Inhibitor

Phases: Phase 1, Phase 2

NCT Number: NCT05451602

URL: https://clinicaltrials.gov/study/NCT05451602

Status: Recruiting